Targeted oncolytic herpes simplex viruses for aggressive cancers

Current Pharmaceutical Biotechnology

Volumn 13, Issue 9, 2012, Pages 1786-1794

  Wong, Jennifer ^a   Lee, Cleo ^b   Zhang, Kevin ^c   Rennie, Paul S ^c   Jia, William ^a,c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b STANFORD UNIVERSITY   (United States)

^c VANCOUVER GENERAL HOSPITAL   (Canada)

Author keywords

Herpes simplex virus type 1; Oncolytic virus; TTDR HSV

Indexed keywords

ARR2 PB ICP4 HSV; CAP BINDING PROTEIN; CARCINOEMBRYONIC ANTIGEN; CMV ICP4 MIR143; CMV ICP4 MIR145; EUKARYOTIC TRANSLATIONAL INITIATION FACTOR 4E; G 207; G92A; KEM34.5; MICRORNA 143; MYB34.5; ONCOLYTIC HERPES VIRUS; PROBASIN; PROTEIN DF3; RNA INDUCED SILENCING COMPLEX; RQNESTIN 34.5; THYMIDINE KINASE; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; BRAIN TUMOR; CANCER CELL CULTURE; CANCER GENE THERAPY; CANCER STEM CELL; CANCER THERAPY; CELL HETEROGENEITY; CELL STRAIN LNCAP; DRUG DESIGN; DRUG MECHANISM; DRUG POTENCY; DRUG SPECIFICITY; GENE EXPRESSION; GLIOBLASTOMA; GLIOMA; HERPES SIMPLEX VIRUS; HUMAN; ICP27 GENE; ICP34.5 GENE; ICP4 GENE; IMMUNE RESPONSE; LIVER CELL CARCINOMA; LIVER TUMOR; MALIGNANT NEOPLASTIC DISEASE; NEUROTOXICITY; NONHUMAN; PROSTATE CANCER; PROSTATE TUMOR; PROTEIN EXPRESSION; REVIEW; RNA TRANSCRIPTION; TRANSCRIPTION REGULATION; TRANSLATION REGULATION; TUMOR CELL; TUMOR XENOGRAFT; VIRUS GENE; VIRUS REPLICATION; VIRUS VIRULENCE;

ANIMALS; DNA REPLICATION; GENETIC THERAPY; HUMANS; NEOPLASMS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; SIMPLEXVIRUS;

ANIMALIA; HARNESS; HUMAN HERPESVIRUS 1; SIMPLEXVIRUS;

EID: 84863539701     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920112800958751     Document Type: Review

References (69)

1. Roizman, B.; Sears, A. Herpes Simplex Viruses and Their Replication. New York Raven Press, 1990; p 1795-1841.
2. Sandri-Goldin, R. M. The many roles of the regulatory protein ICP27 during herpes simplex virus infection. Front Biosci., 2008, 13, 5241-5256.
3. Hagmann, M.; Georgiev, O.; Schaffner, W.; Douville, P., Transcription factors interacting with herpes simplex virus alpha gene promoters in sensory neurons. Nucleic Acids Res., 1995, 23(24), 4978-4985.
4. Zimmer, S. G.; DeBenedetti, A.; Graff, J. R. Translational control of malignancy: the mRNA cap-binding protein, eIF-4E, as a central regulator of tumor formation, growth, invasion and metastasis. Anticancer Res., 2000, 20(3A), 1343-1351.
5. Jia, W.; Zhou, Q. Viral vectors for cancer gene therapy: viral dissemination and tumor targeting. Curr. Gene Ther., 2005, 5(1), 133-142.
6. Mineta, T.; Rabkin, S. D.; Yazaki, T.; Hunter, W. D.; Martuza, R. L. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat. Med., 1995, 1(9), 938-943.
7. Kit, S.; Sheppard, M.; Ichimura, H.; Nusinoff-Lehrman, S.; Ellis, M. N.; Fyfe, J. A.; Otsuka, H. Nucleotide sequence changes in thymidine kinase gene of herpes simplex virus type 2 clones from an isolate of a patient treated with acyclovir. Antimicrob. Agents Chemother., 1987, 31(10), 1483-1490.
8. Larder, B. A.; Cheng, Y. C.; Darby, G. Characterization of abnormal thymidine kinases induced by drug-resistant strains of herpes simplex virus type 1. J. Gen. Virol., 1983, 64 Pt 3, 523-532.
9. Larder, B. A.; Derse, D.; Cheng, Y. C.; Darby, G. Properties of purified enzymes induced by pathogenic drug-resistant mutants of herpes simplex virus. Evidence for virus variants expressing normal DNA polymerase and altered thymidine kinase. J. Biol. Chem., 1983, 258(3), 2027-2033.
10. Martuza, R. L.; Malick, A.; Markert, J. M.; Ruffner, K. L.; Coen, D. M. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science, 1991, 252 (5007), 854-856.
11. Kaplitt, M. G.; Tjuvajev, J. G.; Leib, D. A.; Berk, J.; Pettigrew, K. D.; Posner, J. B.; Pfaff, D. W.; Rabkin, S. D.; Blasberg, R. G. Mutant herpes simplex virus induced regression of tumors growing in immunocompetent rats. J. Neurooncol., 1994, 19(2), 137-147.
12. Jia, W.; McDermotte, M.; al, e. Selective destruction of gliomas in imunocompenent rats by thymidine kinase-defective herpes simplex virus type-1. J. Natl. Cancer Inst., 1994, 86, 1209-1215.
13. Jia, W. W.; Tan, J.; Redekop, G. J.; Goldie, J. H. Toxicity studies in thymidine kinase-deficient herpes simplex virus therapy for malignant astrocytoma. J. Neurosurg., 1996, 85(4), 662-666.
14. Chou, J.; Chen, J. J.; Gross, M.; Roizman, B. Association of a M(r) 90,000 phosphoprotein with protein kinase PKR in cells exhibiting enhanced phosphorylation of translation initiation factor eIF-2 alpha and premature shutoff of protein synthesis after infection with gamma 134.5- mutants of herpes simplex virus 1. Proc. Natl. Acad. Sci. USA, 1995, 92 (23), 10516-10520.
15. He, B.; Gross, M.; Roizman, B. The gamma(1)34.5 protein of herpes simplex virus 1 complexes with protein phosphatase 1alpha to dephosphorylate the alpha subunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by double-stranded RNA-activated protein kinase. Proc. Natl. Acad. Sci. USA, 1997, 94(3), 843-848.
16. Yazaki, T.; Manz, H. J.; Rabkin, S. D.; Martuza, R. L. Treatment of human malignant meningiomas by G207, a replication- competent multimutated herpes simplex virus 1. Cancer Res., 1995, 55(21), 4752-4756.
17. Markert, J. M.; Medlock, M. D.; Rabkin, S. D.; Gillespie, G. Y.; Todo, T.; Hunter, W. D.; Palmer, C. A.; Feigenbaum, F.; Tornatore, C.; Tufaro, F.; Martuza, R. L. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene. Ther., 2000, 7(10), 867-874.
18. Rampling, R.; Cruickshank, G.; Papanastassiou, V.; Nicoll, J.; Hadley, D.; Brennan, D.; Petty, R.; MacLean, A.; Harland, J.; McKie, E.; Mabbs, R.; Brown, M. Toxicity evaluation of replication- competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene. Ther., 2000, 7(10), 859-866.
19. Markert, J. M.; Liechty, P. G.; Wang, W.; Gaston, S.; Braz, E.; Karrasch, M.; Nabors, L. B.; Markiewicz, M.; Lakeman, A. D.; Palmer, C. A.; Parker, J. N.; Whitley, R. J.; Gillespie, G. Y. Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM. Mol. Ther., 2009, 17(1), 199-207.
20. Kelland, L. R. Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug development. Eur. J. Cancer, 2004, 40(6), 827-836.
21. Sallinen, S. L.; Sallinen, P.; Ahlstedt-Soini, M.; Haapasalo, H.; Helin, H.; Isola, J.; Karhu, R. Arm-specific multicolor fluorescence in situ hybridization reveals widespread chromosomal instability in glioma cell lines. Cancer Genet. Cytogenet., 2003, 144(1), 52-60.
22. Saito, T.; Hama, S.; Izumi, H.; Yamasaki, F.; Kajiwara, Y.; Matsuura, S.; Morishima, K.; Hidaka, T.; Shrestha, P.; Sugiyama, K.; Kurisu, K. Centrosome amplification induced by survivin suppression enhances both chromosome instability and radiosensitivity in glioma cells. Br. J. Cancer, 2008, 98 (2), 345-355.
23. Huszthy, P. C.; Goplen, D.; Thorsen, F.; Immervoll, H.; Wang, J.; Gutermann, A.; Miletic, H.; Bjerkvig, R. Oncolytic herpes simplex virus type-1 therapy in a highly infiltrative animal model of human glioblastoma. Clin. Cancer Res., 2008, 14(5), 1571-1580.
24. Wakimoto, H.; Johnson, P. R.; Knipe, D. M.; Chiocca, E. A. Effects of innate immunity on herpes simplex virus and its ability to kill tumor cells. Gene. Ther., 2003, 10(11), 983-990.
25. Todo, T.; Rabkin, S. D.; Sundaresan, P.; Wu, A.; Meehan, K. R.; Herscowitz, H. B.; Martuza, R. L. Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication- competent herpes simplex virus. Hum. Gene. Ther., 1999, 10(17), 2741-2755.
26. Sauthoff, H.; Hu, J.; Maca, C.; Goldman, M.; Heitner, S.; Yee, H.; Pipiya, T.; Rom, W. N.; Hay, J. G. Intratumoral spread of wild-type adenovirus is limited after local injection of human xenograft tumors: virus persists and spreads systemically at late time points. Hum. Gene. Ther., 2003, 14(5), 425-433.
27. Liu, B. L.; Robinson, M.; Han, Z. Q.; Branston, R. H.; English, C.; Reay, P.; McGrath, Y.; Thomas, S. K.; Thornton, M.; Bullock, P.; Love, C. A.; Coffin, R. S. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene. Ther., 2003, 10(4), 292-303.
28. Wakimoto, H.; Kesari, S.; Farrell, C. J.; Curry, W. T., Jr.; Zaupa, C.; Aghi, M.; Kuroda, T.; Stemmer-Rachamimov, A.; Shah, K.; Liu, T. C.; Jeyaretna, D. S.; Debasitis, J.; Pruszak, J.; Martuza, R. L.; Rabkin, S. D. Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors. Cancer Res., 2009, 69(8), 3472-3481.
29. Singh, S. K.; Hawkins, C.; Clarke, I. D.; Squire, J. A.; Bayani, J.; Hide, T.; Henkelman, R. M.; Cusimano, M. D.; Dirks, P. B. Identification of human brain tumour initiating cells. Nature, 2004, 432(7015), 396-401.
30. Bao, S.; Wu, Q.; McLendon, R. E.; Hao, Y.; Shi, Q.; Hjelmeland, A. B.; Dewhirst, M. W.; Bigner, D. D.; Rich, J. N. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature, 2006, 444(7120), 756-760.
31. Eramo, A.; Ricci-Vitiani, L.; Zeuner, A.; Pallini, R.; Lotti, F.; Sette, G.; Pilozzi, E.; Larocca, L. M.; Peschle, C.; De Maria, R. Chemotherapy resistance of glioblastoma stem cells. Cell Death Differ., 2006, 13(7), 1238-1241.
32. Ma, S.; Lee, T. K.; Zheng, B. J.; Chan, K. W.; Guan, X. Y. CD133 HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene, 2008, 27(12), 1749-1758.
33. Tamura, K.; Aoyagi, M.; Wakimoto, H.; Ando, N.; Nariai, T.; Yamamoto, M.; Ohno, K. Accumulation of CD133-positive glioma cells after high-dose irradiation by Gamma Knife surgery plus external beam radiation. J. Neurosurg., 2010, 113(2),310-318.
34. Wang, J.; Wakeman, T. P.; Lathia, J. D.; Hjelmeland, A. B.; Wang, X. F.; White, R. R.; Rich, J. N.; Sullenger, B. A. Notch promotes radioresistance of glioma stem cells. Stem Cells, 28 (1), 17-28.
35. Miyatake, S. I.; Tani, S.; Feigenbaum, F.; Sundaresan, P.; Toda, H.; Narumi, O.; Kikuchi, H.; Hashimoto, N.; Hangai, M.; Martuza, R. L.; Rabkin, S. D. Hepatoma-specific antitumor activity of an albumin enhancer/promoter regulated herpes simplex virus in vivo. Gene. Ther., 1999, 6(4), 564-572.
36. Powell, D. J.; Friedman, J. M.; Oulette, A. J.; Krauter, K. S.; Darnell, J. E. Jr., Transcriptional and post-transcriptional control of specific messenger RNAs in adult and embryonic liver. J. Mol. Biol., 1984, 179(1), 21-35.
37. Chung, R. Y.; Saeki, Y.; Chiocca, E. A. B-myb promoter retargeting of herpes simplex virus gamma34.5 gene-mediated virulence toward tumor and cycling cells. J. Virol., 1999, 73 (9), 7556-7564.
38. Nakamura, H.; Kasuya, H.; Mullen, J. T.; Yoon, S. S.; Pawlik, T. M.; Chandrasekhar, S.; Donahue, J. M.; Chiocca, E. A.; Chung, R. Y.; Tanabe, K. K. Regulation of herpes simplex virus gamma(1)34.5 expression and oncolysis of diffuse liver metastases by Myb34.5. J. Clin. Invest., 2002, 109(7), 871-882.
39. Mullen, J. T.; Kasuya, H.; Yoon, S. S.; Carroll, N. M.; Pawlik, T. M.; Chandrasekhar, S.; Nakamura, H.; Donahue, J. M.; Tanabe, K. K. Regulation of herpes simplex virus 1 replication using tumorassociated promoters. Ann. Surg., 2002, 236(4), 502-512. discussion 512-3.
40. Kambara, H.; Okano, H.; Chiocca, E. A.; Saeki, Y. An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor. Cancer Res., 2005, 65(7), 2832-2839.
41. Kanai, R.; Tomita, H.; Hirose, Y.; Ohba, S.; Goldman, S.; Okano, H.; Kawase, T.; Yazaki, T. Augmented therapeutic efficacy of an oncolytic herpes simplex virus type 1 mutant expressing ICP34.5 under the transcriptional control of musashi1 promoter in the treatment of malignant glioma. Hum. Gene. Ther., 2007, 18(1), 63-73.
42. Rennie, P. S.; Bruchovsky, N.; Leco, K. J.; Sheppard, P. C.; McQueen, S. A.; Cheng, H.; Snoek, R.; Hamel, A.; Bock, M. E.; MacDonald, B. S. Characterization of two cis-acting DNA elements involved in the androgen regulation of the probasin gene. Mol. Endocrinol., 1993, 7 (1), 23-36.
43. Yu, D.; Jia, W. W.; Gleave, M. E.; Nelson, C. C.; Rennie, P. S. Prostate-tumor targeting of gene expression by lentiviral vectors containing elements of the probasin promoter. Prostate, 2004, 59(4), 370-382.
44. Lee, C. Y.; Bu, L. X.; Rennie, P. S.; Jia, W. W. An HSV-1 amplicon system for prostate-specific expression of ICP4 to complement oncolytic viral replication for in vitro and in vivo treatment of prostate cancer cells. Cancer Gene. Ther., 2007, 14(7), 652-660.
45. Yang, C. T.; Song, J.; Bu, X.; Cong, Y. S.; Bacchetti, S.; Rennie, P.; Jia, W. W. Herpes simplex virus type-1 infection upregulates cellular promoters and telomerase activity in both tumor and nontumor human cells. Gene. Ther., 2003, 10(17), 1494-1502.
46. Lee, R. C.; Feinbaum, R. L.; Ambros, V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell, 1993, 75(5), 843-854.
47. Lagos-Quintana, M.; Rauhut, R.; Lendeckel, W.; Tuschl, T. Identification of novel genes coding for small expressed RNAs. Science, 2001, 294(5543), 853-858.
48. Lagos-Quintana, M.; Rauhut, R.; Meyer, J.; Borkhardt, A.; Tuschl, T. New microRNAs from mouse and human. RNA, 2003, 9(2), 175-179.
49. DeSano, J. T.; Xu, L. MicroRNA regulation of cancer stem cells and therapeutic implications. AAPS J., 2009, 11(4), 682-692.
50. Schickel, R.; Boyerinas, B.; Park, S. M.; Peter, M. E. MicroRNAs: key players in the immune system, differentiation, tumorigenesis and cell death. Oncogene, 2008, 27(45), 5959-5974.
51. Kefas, B.; Comeau, L.; Floyd, D. H.; Seleverstov, O.; Godlewski, J.; Schmittgen, T.; Jiang, J.; diPierro, C. G.; Li, Y.; Chiocca, E. A.; Lee, J.; Fine, H.; Abounader, R.; Lawler, S.; Purow, B. The neuronal microRNA miR-326 acts in a feedback loop with notch and has therapeutic potential against brain tumors. J. Neurosci., 2009, 29(48), 15161-15168.
52. Lee, C.; Rennie, P. S.; Jia, W. MicroRNA regulation of oncolytic herpes simplex virus type 1 for selective killing of prostate cancer cells. Clin. Cancer Res., 2009, 15(16),5126-35.
53. De Benedetti, A.; Graff, J. R. eIF-4E expression and its role in malignancies and metastases. Oncogene, 2004, 23(18), 3189-3199.
54. Kevil, C.; Carter, P.; Hu, B.; DeBenedetti, A. Translational enhancement of FGF-2 by eIF-4 factors, and alternate utilization of CUG and AUG codons for translation initiation. Oncogene, 1995, 11 (11), 2339-2348.
55. Kevil, C. G.; De Benedetti, A.; Payne, D. K.; Coe, L. L.; Laroux, F. S.; Alexander, J. S. Translational regulation of vascular permeability factor by eukaryotic initiation factor 4E: implications for tumor angiogenesis. Int. J. Cancer, 1996, 65(6), 785-790.
56. Jiang, Y.; Muschel, R. J. Regulation of matrix metalloproteinase-9 (MMP-9) by translational efficiency in murine prostate carcinoma cells. Cancer Res., 2002, 62(6), 1910-1914.
57. Yu, D.; Scott, C.; Jia, W. W.; De Benedetti, A.; Williams, B. J.; Fazli, L.; Wen, Y.; Gleave, M.; Nelson, C.; Rennie, P. S. Targeting and killing of prostate cancer cells using lentiviral constructs containing a sequence recognized by translation factor eIF4E and a prostate-specific promoter. Cancer Gene. Ther., 2006, 13(1), 32-43.
58. Lee, C. Y.; Bu, L. X.; Debenedetti, A.; Williams, B. J.; Rennie, P. S.; Jia, W. W. Transcriptional and translational dual-regulated oncolytic herpes simplex virus type 1 for targeting prostate tumors. Mol. Ther., 18(5),929-935
59. Smith, C. A.; Bates, P.; Rivera-Gonzalez, R.; Gu, B.; DeLuca, N. A. ICP4, the major transcriptional regulatory protein of herpes simplex virus type 1, forms a tripartite complex with TATAbinding protein and TFIIB. J. Virol., 1993, 67(8), 4676-4687.
60. Shackleton, M.; Quintana, E.; Fearon, E. R.; Morrison, S. J. Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell, 2009, 138(5), 822-829.
61. Tomasson, M. H., Cancer stem cells: a guide for skeptics. J. Cell Biochem., 2009, 106(5), 745-749.
62. Ogden, A. T.; Waziri, A. E.; Lochhead, R. A.; Fusco, D.; Lopez, K.; Ellis, J. A.; Kang, J.; Assanah, M.; McKhann, G. M.; Sisti, M. B.; McCormick, P. C.; Canoll, P.; Bruce, J. N., Identification of A2B5+CD133- tumor-initiating cells in adult human gliomas. Neurosurgery, 2008, 62(2), 505-514. discussion 514-5.
63. Beier, D.; Hau, P.; Proescholdt, M.; Lohmeier, A.; Wischhusen, J.; Oefner, P. J.; Aigner, L.; Brawanski, A.; Bogdahn, U.; Beier, C. P. CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res., 2007, 67(9), 4010-4015.
64. Soeda, A.; Park, M.; Lee, D.; Mintz, A.; Androutsellis-Theotokis, A.; McKay, R. D.; Engh, J.; Iwama, T.; Kunisada, T.; Kassam, A. B.; Pollack, I. F.; Park, D. M. Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF- 1alpha. Oncogene, 2009, 28(45), 3949-3959.
65. Read, T. A.; Fogarty, M. P.; Markant, S. L.; McLendon, R. E.; Wei, Z.; Ellison, D. W.; Febbo, P. G.; Wechsler-Reya, R. J. Identification of CD15 as a marker for tumor-propagating cells in a mouse model of medulloblastoma. Cancer Cell, 2009, 15(2), 135-147.
66. Chen, R.; Nishimura, M. C.; Bumbaca, S. M.; Kharbanda, S.; Forrest, W. F.; Kasman, I. M.; Greve, J. M.; Soriano, R. H.; Gilmour, L. L.; Rivers, C. S.; Modrusan, Z.; Nacu, S.; Guerrero, S.; Edgar, K. A.; Wallin, J. J.; Lamszus, K.; Westphal, M.; Heim, S.; James, C. D.; VandenBerg, S. R.; Costello, J. F.; Moorefield, S.; Cowdrey, C. J.; Prados, M.; Phillips, H. S. A hierarchy of selfrenewing tumor-initiating cell types in glioblastoma. Cancer Cell, 17(4), 362-375.
67. Sharma, S. V.; Lee, D. Y.; Li, B.; Quinlan, M. P.; Takahashi, F.; Maheswaran, S.; McDermott, U.; Azizian, N.; Zou, L.; Fischbach, M. A.; Wong, K. K.; Brandstetter, K.; Wittner, B.; Ramaswamy, S.; Classon, M.; Settleman, J. A chromatin-mediated reversible drugtolerant state in cancer cell subpopulations. Cell, 141(1), 69-80.
68. Otsuki, A.; Patel, A.; Kasai, K.; Suzuki, M.; Kurozumi, K.; Chiocca, E. A.; Saeki, Y. Histone deacetylase inhibitors augment antitumor efficacy of herpes-based oncolytic viruses. Mol. Ther., 2008, 16(9), 1546-1555.
69. Glass, R.; Synowitz, M.; Kronenberg, G.; Walzlein, J. H.; Markovic, D. S.; Wang, L. P.; Gast, D.; Kiwit, J.; Kempermann, G.; Kettenmann, H. Glioblastoma-induced attraction of endogenous neural precursor cells is associated with improved survival. J. Neurosci., 2005, 25 (10), 2637-2646.